Polycarbophil
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
NOTE: Most over the counter (OTC) are not reviewed and approved by the FDA. However, they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.
Overview
Polycarbophil is a laxative that is FDA approved for the treatment of relieves occasional constipation to help restore and maintain regularity this product generally produces bowel movement in 12 to 72 hours. Common adverse reactions include epigastric fullness, flatulence.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
- Relieves occasional constipation to help restore and maintain regularity
this product generally produces bowel movement in 12 to 72 hours take each dose of this product with at least 8 ounces (a full glass) of water or other fluid. Taking this product without enough liquid may cause choking. See CHOKING warning.
- FiberCon works naturally so continued use for one to three days is normally required to provide full benefit. Dosage may vary according to diet, exercise, previous laxative use or severity of constipation.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Polycarbophil in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Polycarbophil in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding FDA-Labeled Use of Polycarbophil in pediatric patients.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Polycarbophil in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Polycarbophil in pediatric patients.
Contraindications
There is limited information regarding Polycarbophil Contraindications in the drug label.
Warnings
- Choking:
- Taking this product without adequate fluid may cause it to swell and block your throat or esophagus and may cause choking. Do not take this product if you have difficulty in swallowing. If you experience chest pain, vomiting, or difficulty in swallowing or breathing after taking this product, seek immediate medical attention.
- Ask a doctor before use if you have
- Abdominal pain, nausea, or vomiting
- A sudden change in bowel habits that persists over a period of 2 weeks
- Ask a doctor or pharmacist before use if you are
- Taking any other drug. Take this product 2 or more hours before or after other drugs. All laxatives may affect how other drugs work.
- When using this product
- Do not use for more than 7 days unless directed by a doctor
- Do not take more than 8 caplets in a 24 hour period unless directed by a doctor
- Stop use and ask a doctor if
- Rectal bleeding occurs or if you fail to have a bowel movement after use of this or any other laxative. These could be signs of a serious condition.
- Keep out of reach of children.
- In case of overdose, get medical help or contact a Poison Control Center right away.
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of Polycarbophil in the drug label.
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Polycarbophil in the drug label.
Drug Interactions
There is limited information regarding Polycarbophil Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
- Pregnancy Category
- Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Polycarbophil in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Polycarbophil during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Polycarbophil with respect to nursing mothers.
Pediatric Use
There is no FDA guidance on the use of Polycarbophil with respect to pediatric patients.
Geriatic Use
There is no FDA guidance on the use of Polycarbophil with respect to geriatric patients.
Gender
There is no FDA guidance on the use of Polycarbophil with respect to specific gender populations.
Race
There is no FDA guidance on the use of Polycarbophil with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Polycarbophil in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Polycarbophil in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Polycarbophil in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Polycarbophil in patients who are immunocompromised.
Administration and Monitoring
Administration
Monitoring
There is limited information regarding Monitoring of Polycarbophil in the drug label.
IV Compatibility
There is limited information regarding IV Compatibility of Polycarbophil in the drug label.
Overdosage
There is limited information regarding Polycarbophil overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
Mechanism of Action
There is limited information regarding Polycarbophil Mechanism of Action in the drug label.
Structure
There is limited information regarding Polycarbophil Structure in the drug label.
Pharmacodynamics
There is limited information regarding Pharmacodynamics of Polycarbophil in the drug label.
Pharmacokinetics
There is limited information regarding Pharmacokinetics of Polycarbophil in the drug label.
Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of Polycarbophil in the drug label.
Clinical Studies
There is limited information regarding Clinical Studies of Polycarbophil in the drug label.
How Supplied
There is limited information regarding Polycarbophil How Supplied in the drug label.
Storage
There is limited information regarding Polycarbophil Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Polycarbophil |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Polycarbophil |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Patient Counseling Information of Polycarbophil in the drug label.
Precautions with Alcohol
- Alcohol-Polycarbophil interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
- FIBERCON ®[1]
Look-Alike Drug Names
There is limited information regarding Polycarbophil Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
{{#subobject:
|Label Page=Polycarbophil |Label Name=Fiber 0n 01.jpg
}}
{{#subobject:
|Label Page=Polycarbophil |Label Name=DailyMed - FIBERCON- calcium polycarbophil tablet .png
}}
{{#subobject:
|Page Name=Polycarbophil |Pill Name=KONSYL_Daily_Therapy_Fiber_NDC_02240500.jpg |Drug Name=KONSYL Daily Therapy Fiber |Pill Ingred=CALCIUM POLYCARBOPHIL[POLYCARBOPHIL]|+sep=; |Pill Imprint=G147 |Pill Dosage=625 mg |Pill Color=White|+sep=; |Pill Shape=Oval |Pill Size (mm)=19 |Pill Scoring=1 |Pill Image= |Drug Author=Konsyl Pharmaceuticals, Inc. |NDC=02240500
}}
{{#subobject:
|Page Name=Polycarbophil |Pill Name=Fiber_Lax_NDC_05364306.jpg |Drug Name=Fiber Lax |Pill Ingred=CALCIUM POLYCARBOPHIL[POLYCARBOPHIL]|+sep=; |Pill Imprint=CPC;339 |Pill Dosage=625 mg |Pill Color=White|+sep=; |Pill Shape=Oval |Pill Size (mm)=19 |Pill Scoring=2 |Pill Image= |Drug Author=Rugby Laboratories |NDC=05364306
}}
{{#subobject:
|Page Name=Polycarbophil |Pill Name=FiberTab_NDC_06030181.jpg |Drug Name=FiberTab |Pill Ingred=CALCIUM POLYCARBOPHIL[POLYCARBOPHIL]|+sep=; |Pill Imprint=AZ221 |Pill Dosage=625 mg |Pill Color=White|+sep=; |Pill Shape=Oval |Pill Size (mm)=19 |Pill Scoring=1 |Pill Image= |Drug Author=Qualitest Pharmaceuticals |NDC=06030181
}}
{{#subobject:
|Page Name=Polycarbophil |Pill Name=FIBER_TABS_NDC_09042500.jpg |Drug Name=FIBER TABS |Pill Ingred=CALCIUM POLYCARBOPHIL[POLYCARBOPHIL]|+sep=; |Pill Imprint=CPC;339 |Pill Dosage=500 mg |Pill Color=Grey|+sep=; |Pill Shape=Oval |Pill Size (mm)=20 |Pill Scoring=2 |Pill Image= |Drug Author=Major Pharmaceuticals |NDC=09042500
}}